On Monday, shares tumbled 20% after the company ... The company hasn’t provided a recent update on the trial. A different biotech, Arcturus Therapeutics, said Friday that it had started ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...

Collectively, these elements underscore Arcturus Therapeutics’ capacity for innovation and market penetration, justifying the Buy rating. ARCT’s price has also changed moderately for the past ...

The 4th T-20 of five-match series between Pakistan and New Zealand will be played in Rawalpindi on Thursday. The match will start at 9 pm. Pakistan lead the series 2-1.